Acquirer(s)
- CSL Limited
Target(s)
- Talecris Biotherapeutics Holdings Corp.
Summary
CSL Limited (CSL) proposes to acquire Talecris Biotherapeutics Holdings Corp. (Talecris)Market definition
The ACCC considered the proposed acquisition in the context of the Australian national market for the supply of plasma products.Competition analysis
On 7 November 2008, the ACCC formed the view that the proposed acquisition was unlikely to substantially lessen competition due to the limited overlap between the merger parties in Australia. Post acquisition the merged entity would continue to face effective competition for the supply of imported plasma products from other significant global suppliers.Timeline
| Date | Event |
|---|---|
ACCC commenced review under the Mergers Review Process Guidelines. |
|
Closing date for submissions from relevant parties. |
|
ACCC announced it would not oppose the proposed acquisition. |